Lebrikizumab Found Effective for Patients With AD, SOC
SAN DIEGO — Among patients with skin of color and moderate to severe atopic dermatitis (AD) who underwent 16 weeks ...
Read moreSAN DIEGO — Among patients with skin of color and moderate to severe atopic dermatitis (AD) who underwent 16 weeks ...
Read moreLebrikizumab, an investigational interleukin-13 inhibitor, showed significant efficacy compared with placebo across racial and ethnic subgroups in patients with moderate-to-severe ...
Read more© 2023 earth-news.info
. . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . %%%. . . . . . 34 Erreur : SQLSTATE[HY000] [1045] Access denied for user 'good-news'@'localhost' (using password: YES)45 Erreur : SQLSTATE[HY000] [1045] Access denied for user 'good-news'@'localhost' (using password: YES)